全文获取类型
收费全文 | 3686篇 |
免费 | 139篇 |
国内免费 | 198篇 |
专业分类
耳鼻咽喉 | 66篇 |
儿科学 | 130篇 |
妇产科学 | 48篇 |
基础医学 | 890篇 |
口腔科学 | 20篇 |
临床医学 | 312篇 |
内科学 | 1253篇 |
皮肤病学 | 116篇 |
神经病学 | 251篇 |
特种医学 | 54篇 |
外科学 | 144篇 |
综合类 | 303篇 |
预防医学 | 99篇 |
眼科学 | 46篇 |
药学 | 199篇 |
1篇 | |
中国医学 | 35篇 |
肿瘤学 | 56篇 |
出版年
2024年 | 2篇 |
2023年 | 62篇 |
2022年 | 162篇 |
2021年 | 171篇 |
2020年 | 152篇 |
2019年 | 162篇 |
2018年 | 190篇 |
2017年 | 144篇 |
2016年 | 178篇 |
2015年 | 116篇 |
2014年 | 312篇 |
2013年 | 373篇 |
2012年 | 189篇 |
2011年 | 199篇 |
2010年 | 161篇 |
2009年 | 180篇 |
2008年 | 161篇 |
2007年 | 156篇 |
2006年 | 147篇 |
2005年 | 115篇 |
2004年 | 91篇 |
2003年 | 77篇 |
2002年 | 54篇 |
2001年 | 46篇 |
2000年 | 56篇 |
1999年 | 25篇 |
1998年 | 35篇 |
1997年 | 36篇 |
1996年 | 25篇 |
1995年 | 25篇 |
1994年 | 24篇 |
1993年 | 57篇 |
1992年 | 15篇 |
1991年 | 15篇 |
1990年 | 18篇 |
1989年 | 13篇 |
1988年 | 13篇 |
1987年 | 11篇 |
1986年 | 8篇 |
1985年 | 3篇 |
1984年 | 11篇 |
1983年 | 3篇 |
1982年 | 4篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1974年 | 4篇 |
排序方式: 共有4023条查询结果,搜索用时 0 毫秒
91.
92.
《Gastroenterologia y hepatologia》2022,45(7):561-570
Budesonide is a glucocorticoid characterized by its local action, with a low systemic bioavailability. Since the original trial comparing budesonide with prednisone in 2010, it is recommended as an effective alternative for the treatment of non-severe acute or chronic autoimmune hepatitis. In this document, we review the general pharmacologic properties of glucocorticoids, the available evidence for the use of budesonide as first line option for autoimmune hepatitis as well as the safety profile of the drug. 相似文献
93.
94.
95.
K. Sndergaard J. Carstens H. Zachariae 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》1997,1(2):155-158
Abstract: Glucocorticoids and immunosuppressive agents can induce remission in most pemphigus patients, but mortality remains at 5 to 15% as a result of side effects. We reviewed the adjunctive effect of long-term plasmapheresis in 8 pemphigus patients. Four cases had been resistant to conventional therapy. One or 2 large-volume plasmapheresis treatments were given monthly over 5 to 141 months. All patients, were in clinical remission within 2 months. Relapses seldom occurred: the patients stayed in remission 90% (40–94) (median, ranges) of the period. In all cases the daily dose of glucocorticoid was reduced. The prednisone level could be decreased from 38 (15–80) mg/day to 7.5 (2.5–35) mg/day (p = 0.002). The overall level of other immunosuppressive agents remained unchanged, except in 1 patient for whom cyclosporine was introduced. This indicates that long-term plasmapheresis could have a steroid-sparing effect and clinical efficacy in pemphigus.— 相似文献
96.
Overlap syndromes among autoimmune liver diseases 总被引:4,自引:0,他引:4
The three major immune disorders of the liver are autoimmune hepatitis(AIH),primary biliary cirrhosis(PBC) and primary sclerosing cholangitis(PSC).Variant forms of these diseases are generally called overlap syndromes,although there has been no standardised definition.Patients with overlap syndromes present with both hepatitic and cholestatic serum liver tests and have histological features of AIH and PBC or PSC.The AIH-PBC overlap syndrome is the most common form,affecting almost 10% of adults with AIH or PBC.Single cases of AIH and autoimmune cholangitis(AMA-negative PBC) overlap syndrome have also been reported.The AIH-PSC overlap syndrome is predominantly found in children,adolescents and young adults with AIH or PSC.Interestingly,transitions from one autoimmune to another have also been reported in a minority of patients,especially transitions from PBC to AIH-PBC overlap syndrome.Overlap syndromes show a progressive course towards liver cirrhosis and liver failure without treatment.Therapy for overlap syndromes is empiric,since controlled trials are not available in these rare disorders.Anticholestatic therapy with ursodeoxycholic acid is usually combined with immunosuppressive therapy with corticosteroids and/or azathioprine in both AIH-PBC and AIH-PSC overlap syndromes.In end-stage disease,liver transplantation is the treatment of choice. 相似文献
97.
《Vaccine》2015,33(30):3444-3449
Whereas safety and efficacy of HPV vaccines in healthy women have been shown in several randomised controlled clinical trials and in post marketing analyses, only few data exist in patients affected by autoimmune diseases. These issues are significant as autoimmune conditions are recognised as a risk factor for the persistence of HPV infection. Herein we review and systematise the existing literature to assess immunogenicity and safety of HPV vaccination in patients with autoimmune diseases, including systemic lupus erythematosus and juvenile idiopathic arthritis.The results of our literature revision suggest that the HPV vaccines are efficacious and safe in most of the patients affected by autoimmune diseases. Yet, some points of concern remain to be tackled, including the effects of concomitant therapies, the risk of disease exacerbation and the cost-effectiveness of such immunisation programmes in these populations. 相似文献
98.
目的:研究雷公藤多苷联合常规治疗对紫癜性肾炎患儿血清学指标的影响.方法:选择2011年3月~2014年6月期间在我院儿科接受治疗的紫癜性肾炎患儿进行研究,随机分为常规治疗组和雷公藤组,检测两组患者的免疫标志分子、细胞因子以及蛋白酶分子含量.结果:(1)免疫标志分子:与常规治疗组血液中免疫标志分子的含量比较,雷公藤组血液中CD28、B7-2、CD54、CD11a、CD11b、CD18的含量较低;(2)细胞因子:与常规治疗组血清细胞因子含量比较,雷公藤组血清中肿瘤坏死因子-a(TNF-α)、转化生长因子-β1(TGF-β1)、胰岛素样生长因子(IGF1)、胰岛素样生长因子结合蛋白IGFBP-3、肝细胞生长因子(HGF)和结缔组织生长因子(CTGF)含量较低;(3)蛋白酶分子:与常规治疗组血清蛋白酶分子含量比较,雷公藤组血清中基质金属蛋白酶2、9(MMP2、MMP9)、胱蛋白酶C(Cys C)含量较低,TIMP1、β1,3半乳糖基转移酶(β1,3GT)、Cosmc含量较高.结论:雷公藤多苷联合常规治疗有助于抑制自身免疫反应,减少紫癜性肾炎相关细胞因子产生,调节蛋白酶平衡,是治疗紫癜性肾炎的理想方法. 相似文献
99.
100.
Akane Hara Tomohiro Watanabe Kosuke Minaga Tomoe Yoshikawa Ken Kamata Masatoshi Kudo 《World journal of gastroenterology : WJG》2021,27(19):2257-2269
Solitary organ autoimmune disorders, formerly known as autoimmune pancreatitis (AIP), autoimmune sialadenitis, and autoimmune sclerosing cholangitis, are now considered organ-specific manifestations of systemic immunoglobulin G4-related disease (IgG4-RD). AIP and IgG4-RD are characterized by elevated serum concentration of IgG4 antibody (Ab), accumulation of IgG4-expressing plasmacytes in the affected organs, and involvement of multiple organs. It is well established that enhanced IgG4 Ab responses are a hallmark of AIP and IgG4-RD for diagnosis and monitoring disease activity. However, a significant fraction of patients with AIP and IgG4-RD who develop chronic fibroinflammatory responses have normal serum concentrations of this IgG subtype. In addition, disease flare-up is sometimes seen even in the presence of normalized serum concentrations of IgG4 Ab after successful induction of remission by prednisolone. Therefore, it is necessary to identify new biomarkers based on the understanding of the pathophysiology of AIP and IgG4-RD. Recently, we found that activation of plasmacytoid dendritic cells producing both interferon-α (IFN-α) and interleukin-33 (IL-33) mediate murine AIP and human IgG4-RD. More importantly, we provided evidence that serum concentrations of IFN-α and IL-33 could be useful biomarkers for the diagnosis and monitoring of AIP and IgG4-RD activity after induction of remission in these autoimmune disorders. In this Frontier article, we have summarized and discussed biomarkers of AIP and IgG4-RD, including Igs, autoAbs, and cytokines to provide useful information not only for clinicians but also for researchers. 相似文献